ORNL meets key FDA milestone for cancer-fighting Ac-225 isotope

A rare isotope in high demand for treating cancer is now more available to pharmaceutical companies developing and testing new drugs. The U.S. Food and Drug Administration recently received Oak Ridge National Laboratory’s drug master file for actinium-225 nitrate, which lets pharmaceutical companies reference the document to support applications for their own Ac-225-based drugs without disclosing proprietary information.